MetLife Investment Management’s Eikon Therapeutics EIKN Stock Holding History

MetLife Investment Management’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$180K	Buy	+13,755	New	+$140K	﹤0.01%	2477

Other funds holding EIKN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

MetLife Investment Management's EIKN Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Eikon Therapeutics (EIKN) in Q2 2026: 13,755 shares worth $180K. The stake represents ﹤0.01% of the portfolio and ranks #2477 among its holdings.

77 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

MetLife Investment Management held 13,755 shares of Eikon Therapeutics worth $180K as of Q2 2026.
Eikon Therapeutics was a new MetLife Investment Management position in Q2 2026.
Eikon Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2477 holding.
77 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.